Australia Health

Biome Australia (ASX:BIO) has reported a 30% increase in preliminary annual sales revenue to $23.9 million for FY26.

Imugene (ASX:IMU) announced that the first patient in its azer-cel Phase 1b trial cohort achieved a complete response.

Recce Pharmaceuticals (ASX:RCE) has secured firm commitments to raise $4 million through a new institutional share placement.

Visionflex (ASX:VFX) has secured an approximately $0.8 million contract with NSW Health to supply clinical hardware.

4DMedical (ASX:4DX) has secured Australian TGA regulatory approval for its CT:VQ non-contrast lung imaging software.

Echo IQ (ASX:EIQ) executed a binding agreement for a proposed investment of up to $20 million and a partnership with Pro Medicus (ASX:PME).

AFT Pharmaceuticals (ASX:AFP) secured US FDA approval to launch a Phase 3 trial targeting a US$7.41 billion market.

Recce Pharmaceuticals (ASX:RCE) received ethical approval to advance its Australian diabetic foot infection trial to a 200-patient Phase 3 study.

Bupa has executed an agreement to acquire Partnered Health Group to grow its integrated healthcare service footprint across Australia.

Cynata Therapeutics (ASX:CYP) announced its Phase 3 trial of CYP-004 showed no statistically significant differences.

Australian Clinical Labs (ASX:ACL) announced it is contacting approximately 280,000 individuals following a cyber incident at its SunDoctors subsidiary.

BCAL Diagnostics (ASX:BDX) has developed a diagnostic blood test that achieved 91% sensitivity for detecting breast cancer recurrence.